Inclusion complex effect on the bioavailability of clotrimazole from poloxamer-based solid suppository
- 1 July 2012
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 35 (7) , 1169-1175
Abstract
To study the effect of β-cyclodextrin (βCD) inclusion complex on the bioavailability of clotrimazole from poloxamer-based suppository, formulations composed of P 188, propylene glycol and different molar ratio of clotrimazole-βCD inclusion complex were prepared. Clotrimazole (1%) has been formulated in a suppository using the thermo sensitive polymer P188 (70%) together with propylene glycol (30%). To increase its aqueous solubility, clotrimazole was incorporated as its inclusion complex at various molar ratios with βCD (1:0.25, 1:0.5, 1:1, and 1:2). The inclusion complex was characterized by differential scanning calorimetry (DSC), XRD and phase solubility studies. It was observed that the complexation with βCD, particularly at high molar ratio (F3 (1:1) and F4 (1:2)) decreased the release profile of clotrimazole considerably. However, suppositories containing inclusion complex at low molar ratio (F1 (1:0.25) and F2 (1:0.5)) showed excellent release profile compared to control formulation. In vivo study in rats at 15 mg/Kg dose showed that the F1 and F2 (82.39 ± 15.40 and 67.05 ± 8.79, respectively) significantly increased the AUC compared to that of F3 (41.48 ± 11.51), F4 (23.34 ± 8.37) and control (46.7 ± 7.87) suppositories. Thus, the suppositories containing inclusion complexes prepared at low drug to βCD molar ratio (F1) could be a potential suppository formulation to increase the bioavailability of hydrophobic drugs such as clotrimazole.Keywords
This publication has 16 references indexed in Scilit:
- Formulation, Characterization, and Clinical Evaluation of Microemulsion Containing Clotrimazole for Topical DeliveryAAPS PharmSciTech, 2011
- Biostable Poly(ethylene oxide)-b-poly(methacrylic acid) Micelles forpH-triggered Release of DoxorubicinJournal of Pharmaceutical Investigation, 2011
- Development of thermo-sensitive injectable hydrogel with sustained release of doxorubicin: Rheological characterization and in vivo evaluation in ratsDrug Delivery, 2011
- Optimized formulation for topical administration of clotrimazole using Pemulen polymeric emulsifierDrug Development and Industrial Pharmacy, 2010
- Clotrimazole induces a late G1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitroAnti-Cancer Drugs, 2010
- A Novel Administration Route of Edaravone – II: Mucosal Absorption of Edaravone from Edaravone/Hydroxypropyl-Beta-Cyclodextrin Complex Solution Including L-Cysteine and Sodium Hydrogen SulfitePharmacology, 2010
- Formulation and evaluation of buccoadhesive tablets of clotrimazoleAsian Journal of Pharmaceutics, 2010
- Microemulsion-Based Vaginal Gel of Clotrimazole: Formulation, In Vitro Evaluation, and Stability StudiesAAPS PharmSciTech, 2009
- Clotrimazole Ameliorates Intestinal Inflammation and Abnormal Angiogenesis by Inhibiting Interleukin-8 Expression through a Nuclear Factor-κB-Dependent MannerThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer–propylene glycol gelInternational Journal of Pharmaceutics, 2006